Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec’s T-SPOT®.TB Test Included in the World Health Organization’s First-Ever Essential Diagnostics List
OXFORD, United Kingdom and MARLBOROUGH, Mass. , May 21, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that the Company’s T-SPOT. TB test for tuberculosis (TB) infection has been included in the World Health
View HTML
Toggle Summary Oxford Immunotec to Present at the 2018 UBS Global Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass. , May 16, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith , Chief Executive Officer, will present at the 2018 UBS Global Healthcare Conference
View HTML
Toggle Summary Oxford Immunotec Reports First Quarter 2018 Financial Results
OXFORD, United Kingdom and MARLBOROUGH, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced first quarter 2018 financial results. “Our first quarter results were in line with our expectations, with
View HTML
Toggle Summary Oxford Immunotec Schedules First Quarter 2018 Earnings Release and Conference Call for May 1, 2018
OXFORD, United Kingdom and MARLBOROUGH, Mass. , April 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2018 financial results prior to market open on Tuesday, May 1 , 2018.  Dr.
View HTML
Toggle Summary Oxford Immunotec to Present at Two Upcoming Investor Conferences
OXFORD, United Kingdom and MARLBOROUGH, Mass. , March 06, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith , Chief Executive Officer, is scheduled to present at the following upcoming
View HTML
Toggle Summary Oxford Immunotec Announces Appointment of Mark Klausner to the Board of Directors
OXFORD, United Kingdom and MARLBOROUGH, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the appointment of Mark Klausner to the Company's Board of Directors. Mr.
View HTML
Toggle Summary Oxford Immunotec Reports Fourth Quarter and Full Year 2017 Financial Results
2017 marks the 13 th consecutive year of at least 20% year-over-year constant currency revenue growth >25% pro forma organic growth for the year in tick-borne disease and other revenue Balance sheet strengthened by December patent infringement settlement, which included a cash receipt of $27.5
View HTML
Toggle Summary Oxford Immunotec Schedules Fourth Quarter and Full Year 2017 Earnings Release and Conference Call for February 27, 2018
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2017 financial results prior to market open on Tuesday,
View HTML
Toggle Summary Oxford Immunotec Announces Preliminary Revenue for Fourth Quarter and Full Year 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that based on preliminary unaudited financial data, the Company expects revenue for the fourth quarter of 2017 will
View HTML
Toggle Summary Oxford Immunotec to Present at the 36th Annual J.P. Morgan Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith , Chief Executive Officer, will present at the 36th Annual J.P.
View HTML